Impact of Protein Source on Gut Health

April 18, 2024 updated by: David Montrose, Stony Brook University

Determining the Effect of Dietary Protein Source on Intestinal Health

The gastrointestinal (GI) tract is a central hub for human health given its essential role in nutrient absorption, waste production and immunity. Diet is a major contributor to gut health including affecting the incidence and severity of GI disease. This is mediated, at least in part, by the presence of microbiota, a highly diet-dependent biome. In fact, dietary changes are capable of altering bacterial populations and/or microbial metabolism, which in turn, controls the type and abundance of small molecules being produced in the gut, many of which can exert biological effects. Several lines of evidence suggest that dietary protein in particular, can impact gut health. Therefore, this trial will test whether dietary protein type differentially impacts gut function in humans by carrying out a single-blinded randomized cross-over controlled feeding study in healthy individuals. Subjects will be provided with an individualized very low protein diet augmented with pea- or egg white-derived protein supplements, as their major protein source. The impact of consuming pea vs. egg white protein on 1) the fecal metabolome, 2) gut barrier function and 3) gastrointestinal symptoms will be determined.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Stony Brook, New York, United States, 11794
        • Stony Brook University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • BMI of 18-29.9

Exclusion Criteria:

  • Those with a history of significant illness including diabetes, renal, liver or cardiovascular disease, malnutrition, GI disease (including IBS, IBD, chronic constipation or diarrhea), mental illness (i.e. depression, bipolar disorder)
  • Those adhering to a vegan diet or vegetarian diet exclusive of eggs
  • Those having taken probiotics or antibiotics within 1 month of starting the study
  • Those who are pregnant or plan to become pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pea protein to egg white protein
This arm will receive 10 days of pea protein isolate followed by 10 days of consuming egg white protein isolate, with the two treatment periods separated by a 14-day washout period.
The indicated protein isolates will be given to subjects as their major protein source
Experimental: Egg white protein to pea protein
This arm will receive 10 days of egg white protein isolate followed by 10 days of consuming pea protein isolate, with the two treatment periods separated by a 14-day washout period.
The indicated protein isolates will be given to subjects as their major protein source

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fecal metabolome
Time Frame: This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
Mass-spectrometry based analysis of the relative abundance of metabolites will be carried out on feces.
This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
Intestinal permeability
Time Frame: This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period
Subjects will undergo lactulose-mannitol test to inform on gut permeability
This analysis will be carried out at baseline and the end of each treatment period, entailing 4 measurements over an approximately 36 day period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to study diets
Time Frame: Daily over two, 10-day periods
consumption of study diets will be recorded through subject-reported surveys before and after eating.
Daily over two, 10-day periods
Amount of study diets consumed
Time Frame: Daily over two, 10-day periods
Subjects will take pictures of food items before and after eating to assess the amount of each study diet item consumed.
Daily over two, 10-day periods

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David C Montrose, PhD, Stony Brook University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 18, 2023

Primary Completion (Actual)

April 28, 2023

Study Completion (Actual)

April 28, 2023

Study Registration Dates

First Submitted

November 9, 2022

First Submitted That Met QC Criteria

November 9, 2022

First Posted (Actual)

November 17, 2022

Study Record Updates

Last Update Posted (Actual)

April 19, 2024

Last Update Submitted That Met QC Criteria

April 18, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2022-00427

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diet, Healthy

Clinical Trials on Protein isolate

Subscribe